HTA23 Restrictions and Real-World Evidence Requirements in the Health Technology Assessment of Gene Therapy Medicinal Products in Europe, Canada, Australia, and the United States
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.1483
https://www.valueinhealthjournal.com/article/S1098-3015(22)03688-9/fulltext
Title :
HTA23 Restrictions and Real-World Evidence Requirements in the Health Technology Assessment of Gene Therapy Medicinal Products in Europe, Canada, Australia, and the United States
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)03688-9&doi=10.1016/j.jval.2022.09.1483
First page :
Section Title :
Open access? :
No
Section Order :
11032